Adrian Towse, MA, MPhil

Articles by Adrian Towse, MA, MPhil

What Do Pharmaceuticals Really Cost in the Long Run?

ByDarius Lakdawalla, PhD,Joanna P. MacEwan, PhD,Robert Dubois, MD, PhD,Kimberly Westrich, MA,Mikel Berdud, PhD,Adrian Towse, MA, MPhil

August 22nd 2017

This study found that brand price at launch and generic entry overstates long-run average pharmaceutical costs, with and without accounting for medical cost offsets.

Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects

ByLouis P. Garrison Jr, PhD,Josh J. Carlson, PhD,Preeti S. Bajaj, PhD,Adrian Towse, MA, MPhil,Peter J. Neumann, ScD,Sean D. Sullivan, PhD,Kimberly Westrich, MA,Robert W. Dubois, MD, PhD

September 15th 2015

Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.

Latest Updated Articles

Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects
September 15th 2015
What Do Pharmaceuticals Really Cost in the Long Run?
August 22nd 2017

Adrian Towse, MA, MPhil

Articles by Adrian Towse, MA, MPhil

What Do Pharmaceuticals Really Cost in the Long Run?

Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects

Latest Updated Articles

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Monoclonal Antibodies Had Varying Efficacy in Treating MG